Xin Lang Zheng Quan·2025-08-15 01:52Group 1 - Recently, Fosun Pharma successfully issued the first long-term technology innovation bond in the private pharmaceutical sector in China, with a scale of 1 billion RMB, a term of 2 years, and a coupon rate of 2.70% [1] - The bond received enthusiastic subscriptions from various financial institutions, including bank wealth management, insurance, foreign banks, public funds, and securities firms, indicating strong market support [1][2] - The funds raised will provide strong financial support for Fosun Pharma's layout in key technology innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - The issuance of this technology innovation bond aligns with the central government's policies to support the healthy and high-quality development of the private economy, as emphasized in recent meetings and action plans [1][2] - Fosun Pharma has been focusing on innovation as its core development driver for over 30 years, having received approvals for 12 self-developed and licensed innovative drugs since 2019, covering critical treatment areas [3] - The company aims to deepen its innovation transformation and provide high-quality, accessible products and services to patients and customers, while creating sustainable value returns for shareholders [3]